ClinicalTrials.gg
CompletedNCT00744978Updated Nov 22, 2011Results posted

Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease

A Phase 2 interventional study of Varenicline and Placebo in Alzheimer's Disease, sponsored by Pfizer. Completed at 8 sites in Korea, Republic of. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-11-22.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 101 studies in Alzheimer Disease by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Pfizer.

Enrollment
41st of 94
66 · median 56
Started
2009
with 30 others
Phase 2
24 of 101
none open now
Registered
47th of 101
by date

Among the 101 studies in Alzheimer Disease by Pfizer, this one is the 41st largest by enrollment of the 94 interventional ones that give a count, is one of 31 that started in 2009, is one of 24 in phase 2, and was the 47th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 101 studies in Alzheimer Disease by Pfizer is open now. Recruiting first, the newest first:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Alzheimer Disease by Pfizer, or all of them as a file.
02

Study summary

  1. Assess the efficacy of varenicline, relative to placebo, on a performance based measure of cognition in patients with mild to moderate Alzheimer's disease
  2. Evaluate the effects of varenicline on clinically relevant measures including attention and executive function, behavior, and clinician rated global change.
  3. Evaluate the safety and tolerability of varenicline, relative to placebo, in patients with mild to moderate Alzheimer's disease
  4. Evaluate the pharmacokinetics of varenicline in patients with mild to moderate Alzheimer's disease.
03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Efficacy
  • Safety
  • Pharmacokinetics
  • Alzheimer's disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, age 55-85
  • Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) (DSM IV)
  • Mini-mental status exam score of 14-26 inclusive
  • Rosen-Modified Hachinski Ischemia Score of \< or = 4

Exclusion criteria

Exclusion Criteria:

  • Diagnosis or history of other dementia or neurodegenerative disorders
  • Diagnosis or history of cerebrovascular or cardiovascular disease
  • Subjects with pulmonary disease or evidence of clinically significant pulmonary symptoms
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Varenicline

    Drug: Varenicline

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks

    Also known as: Chantix, Champix

  • DrugPlacebo

    Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.

06

What researchers measure

Primary outcomes

  1. Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6

    12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.

    Time frame: Week 6

Secondary outcomes

  1. Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3

    12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.

    Time frame: Week 3

  2. Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3

    11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.

    Time frame: Week 3

  3. Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6

    11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.

    Time frame: Week 6

  4. Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

    Time frame: Week 6

  5. Neuropsychiatric Inventory (NPI) Total Score at Week 3

    Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.

    Time frame: Week 3

  6. Neuropsychiatric Inventory (NPI) Total Score at Week 6

    Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.

    Time frame: Week 6

  7. Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1

    Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 1

  8. Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3

    Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 3

  9. Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6

    Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 6

  10. Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1

    Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

    Time frame: Week 1

  11. Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3

    Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

    Time frame: Week 3

  12. Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6

    Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

    Time frame: Week 6

  13. Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1

    Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 1

  14. Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3

    Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 3

  15. Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6

    Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 6

  16. Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1

    Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 1

  17. Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3

    Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 3

  18. Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6

    Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

    Time frame: Week 6

  19. Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1

    Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 1

  20. Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3

    Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 3

  21. Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6

    Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

    Time frame: Week 6

07

Results

Posted Nov 22, 2011

Participant flow

Period 1
Participant flow — Period 1
MilestoneVarenicline Then PlaceboPlacebo Then Varenicline
Started3234
Treated3133
Completed2629
Not completed65
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject02
Withdrew: Other02
Withdrew: Adverse event40
Withdrew: Randomized but not treated11
Placebo Washout
Participant flow — Placebo Washout
MilestoneVarenicline Then PlaceboPlacebo Then Varenicline
Started2629
Completed2629
Not completed00
Period 2
Participant flow — Period 2
MilestoneVarenicline Then PlaceboPlacebo Then Varenicline
Started2629
Completed2628
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryAlzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6

12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.

Time frame:
Week 6
Reported as:
Least squares mean · units on scale
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6
units on scaleVareniclinePlacebo
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 618.07 ± 0.94218.49 ± 0.939
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.3873 (ANCOVA model using unstructured covariance structure; Type I error rate for primary hypothesis was 5%; no adjustments made for multiplicity.) · Mean difference (final values): -0.42 · 95% CI -1.37 to 0.53
SecondaryAlzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3

12-item scale to assess severity of cognitive impairment in AD. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, remembering test instructions, and concentration/distractibility. Total score range from 0-75 with 75 indicating worse cognition.

Time frame:
Week 3
Reported as:
Least squares mean · units on scale
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 3
units on scaleVareniclinePlacebo
Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 319.87 ± 0.93519.31 ± 0.941
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.2465 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.55 · 95% CI -0.39 to 1.49
SecondaryAlzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3

11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.

Time frame:
Week 3
Reported as:
Least squares mean · units on scale
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3
units on scaleVareniclinePlacebo
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 319.60 ± 0.88019.01 ± 0.885
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.2092 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.59 · 95% CI -0.33 to 1.50
SecondaryAlzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6

11-item scale designed to assess the severity of cognitive impairments in AD subjects. Items include word recall, naming objects and fingers, following commands, constructional praxis, ideational praxis, orientation, word recognition, spoken language ability, comprehension of spoken language, word finding difficulty in spontaneous speech, and remembering test instructions. Total score range from 0-70 with 70 indicating worse cognition.

Time frame:
Week 6
Reported as:
Least squares mean · units on scale
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 6
units on scaleVareniclinePlacebo
Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 617.86 ± 0.88618.23 ± 0.884
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.4339 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.37 · 95% CI -1.30 to 0.56
SecondaryMean Clinical Global Impression - Improvement (CGI-I) Score at Week 6

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 6
units on a scaleVareniclinePlacebo
Mean Clinical Global Impression - Improvement (CGI-I) Score at Week 63.71 ± 0.1033.70 ± 0.102
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.9745 · Mean difference (final values): 0.00 · 95% CI -0.26 to 0.27
SecondaryNeuropsychiatric Inventory (NPI) Total Score at Week 3

Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.

Time frame:
Week 3
Reported as:
Least squares mean · scores on scale
Neuropsychiatric Inventory (NPI) Total Score at Week 3
scores on scaleVareniclinePlacebo
Neuropsychiatric Inventory (NPI) Total Score at Week 32.97 ± 0.8452.29 ± 0.858
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.2852 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.68 · 95% CI -0.57 to 1.92
SecondaryNeuropsychiatric Inventory (NPI) Total Score at Week 6

Caregiver interview-based rating scale assessing 12 behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, appetite/eating, and sleep. Each symptom score derived by frequency of symptoms \* severity of symptoms (range 0-12). Total score = sum of symptom scores; range: 0-144 with higher score indicating greater behavioral disturbances.

Time frame:
Week 6
Reported as:
Least squares mean · scores on scale
Neuropsychiatric Inventory (NPI) Total Score at Week 6
scores on scaleVareniclinePlacebo
Neuropsychiatric Inventory (NPI) Total Score at Week 63.82 ± 0.8572.55 ± 0.855
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.0468 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 1.28 · 95% CI 0.02 to 2.53
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1

Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 1
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 1
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 12.65 ± 0.0152.64 ± 0.015
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.8811 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.00 · 95% CI -0.02 to 0.03
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3

Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 3
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 3
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 32.65 ± 0.0152.63 ± 0.015
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.0830 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.02 · 95% CI -0.00 to 0.05
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6

Assessment of the cognitive domain psychomotor function through yes or no responses within 5 minutes to 30 trials; score range: 0 to 3.69. Performance variable: speed of performance; average of the log10 t transformed reaction time for correct responses. Reaction times longer than 5 seconds (log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 6
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 6
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Detection at Week 62.64 ± 0.0152.65 ± 0.015
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.7226 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.00 · 95% CI -0.03 to 0.02
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1

Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

Time frame:
Week 1
Reported as:
Least squares mean · errors
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 1
errorsVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 138.52 ± 2.58640.05 ± 2.626
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.5588 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -1.53 · 95% CI -6.68 to 3.62
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3

Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

Time frame:
Week 3
Reported as:
Least squares mean · errors
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 3
errorsVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 339.43 ± 2.60043.57 ± 2.656
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.1173 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -4.15 · 95% CI -9.34 to 1.05
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6

Assessment of the cognitive domain visual episodic memory (associate learning) through responses within 7 minutes to 4 targets x 4 rounds (mild AD) or 3 targets x 4 rounds (moderate AD); score range: 35 to 100. Performance variable: number of errors made in correctly placing each of the 4 patterns in their location four times.

Time frame:
Week 6
Reported as:
Least squares mean · errors
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 6
errorsVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Continuous Paired Associate Learning (CPAL) at Week 641.67 ± 2.66842.98 ± 2.641
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.6251 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -1.31 · 95% CI -6.58 to 3.96
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1

Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 1
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 1
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 10.94 ± 0.0310.94 ± 0.031
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.9109 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.00 · 95% CI -0.05 to 0.05
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3

Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 3
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 3
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 30.96 ± 0.0310.97 ± 0.032
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.6632 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.01 · 95% CI -0.06 to 0.04
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6

Assessment of the cognitive domain working memory through yes or no responses to 30 trials within 5 minutes; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 6
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 6
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: One Back Working Memory at Week 60.95 ± 0.0320.96 ± 0.031
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.5450 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.02 · 95% CI -0.07 to 0.04
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1

Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 1
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 1
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 10.83 ± 0.0150.81 ± 0.016
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.2799 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.02 · 95% CI -0.02 to 0.05
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3

Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 3
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 3
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 30.82 ± 0.0160.82 ± 0.016
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.9675 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.00 · 95% CI -0.03 to 0.04
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6

Assessment of the cognitive domain episodic memory through yes or no responses within 5 minutes to 4 targets repeated among 6 distractors on 4 rounds (mild Alzheimer's disease \[AD\], or 3 targets repeated among 4 distractors on 4 rounds (moderate AD) ; score range: 0 to 1.57. Performance variable: accuracy of performance; arcsine transformation of proportion correct responses.

Time frame:
Week 6
Reported as:
Least squares mean · arcsine proportion correct
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 6
arcsine proportion correctVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Visual Learning at Week 60.83 ± 0.0160.84 ± 0.016
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.5008 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.01 · 95% CI -0.05 to 0.02
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1

Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 1
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 1
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 12.79 ± 0.0112.80 ± 0.011
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.2245 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.01 · 95% CI -0.03 to 0.01
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3

Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 3
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 3
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 32.79 ± 0.0112.80 ± 0.011
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.4974 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): -0.01 · 95% CI -0.03 to 0.01
SecondaryComputerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6

Assessment of the cognitive domain visual attention through a yes or no response to 30 trials within 5 minutes; score range: 0 to 3.69. Performance variable: speed of performance; average log10 transformed reaction time for correct responses. Reaction times longer than 5 seconds ( log10 \[5000\]) were excluded as reflecting responses that were abnormally slow.

Time frame:
Week 6
Reported as:
Least squares mean · log10 millisecond
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 6
log10 millisecondVareniclinePlacebo
Computerized Test Battery for Cognition (CogState) Tasks: Identification at Week 62.79 ± 0.0122.79 ± 0.011
Statistical analysis
  • Varenicline vs Placebo · ANCOVA · p = 0.8525 (ANCOVA model using unstructured covariance structure; tested using a nominal 5% Type I error rate; no adjustments made for multiplicity.) · Mean difference (final values): 0.00 · 95% CI -0.02 to 0.02

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—2/60 (3.3%)56/60 (93.3%)
Placebo—0/59 (0%)37/59 (62.7%)
Most frequent serious events
Most frequent serious events
EventVareniclinePlacebo
AstheniaGeneral disorders1/600/59
FractureInjury, poisoning and procedural complications1/600/59
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/600/59
Most frequent other events
Showing 10 of 79
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders17/602/59
Decreased appetiteMetabolism and nutrition disorders13/606/59
VomitingGastrointestinal disorders12/600/59
DizzinessNervous system disorders8/600/59
HeadacheNervous system disorders7/604/59
NasopharyngitisInfections and infestations2/604/59
DyspepsiaGastrointestinal disorders4/601/59
ConstipationGastrointestinal disorders3/602/59
Abdominal pain upperGastrointestinal disorders2/602/59
Urinary tract infectionInfections and infestations2/602/59

Baseline characteristics

Age Continuous
Age Continuous(years)Varenicline Then PlaceboPlacebo Then VareniclineTotal
Mean71.5 ± 8.773.9 ± 5.872.7 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Varenicline Then PlaceboPlacebo Then VareniclineTotal
Female212142
Male111324
08

Study locations

8 sites
  • Pfizer Investigational Site
    Seongnam, Gyunggido 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 602-715, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 700-721, Korea, Republic of
  • Pfizer Investigational Site
    Incheon, 400-711, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 136-705, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 158-710, Korea, Republic of
  • Pfizer Investigational Site
    Suwon, 443-721, Korea, Republic of
09

References and documents

Publications

  • Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, Jacobsen J. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2014;37(3-4):232-45. doi: 10.1159/000355373. Epub 2013 Nov 14. PubMed 24247022 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2008
First posted
Sep 1, 2008
Start
Jul 2009
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Nov 22, 2011
Last update
Nov 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00744978
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 1, 2008
Start date
Jul 2009
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Nov 22, 2011
Last update
Nov 22, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion